Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease
Alimentary Pharmacology & Therapeutics2020Vol. 52(8), pp. 1289–1297
Citations Over TimeTop 10% of 2020 papers
Antoine Chupin, Vittorio Perduca, Antoine Meyer, Christophe Bellanger, Franck Carbonnel, Catherine Dong
Abstract
There is an increased risk of lymphoma in IBD patients treated with anti-TNF agents, either alone or when combined with thiopurines.
Related Papers
- → NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity(2016)461 cited
- → Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment response(2017)38 cited
- → Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity(2018)20 cited
- → P453 Comparison of therapeutic effects between groups of thiopurine alone and combination of thiopurine with 5-ASA after remission introduced by oral tacrolimus for patients with severe ulcerative colitis(2020)
- → The fault…is not in our stars, but in ourselves(2019)